MCL Literature Feed

This case report describes a rare primary cutaneous presentation of mantle cell lymphoma, highlighting the need to consider MCL in the differential diagnosis of new skin masses.

In newly diagnosed MCL, higher total lymphocyte and B-cell counts in the bone marrow correlated with a lower percentage of disease progression, suggesting a potential prognostic flow cytometry biomarker.

Radiotherapy for localized orbital MCL achieves excellent long-term cancer-specific survival (83% at 15 years), supporting its use as a primary treatment, especially for elderly or frail patients.

This first reported case of mantle cell lymphoma with hypereosinophilia demonstrates a rare paraneoplastic presentation where eosinophil counts normalized following successful immunochemotherapy, expanding the disease's clinical spectrum.

In the frontline MANTLE-FIRST study, fitness status and time to first progression (PFS1) were identified as key prognostic factors for elderly MCL patients, impacting subsequent outcomes.

Genomic analysis reveals MCL relapse is driven by pre-existing resistant clones from diagnosis, not new mutations, emphasizing the need for deep upfront responses to eradicate these subclones.

White-centered retinal hemorrhages (Roth spots) can be the initial presenting sign of an otherwise hidden mantle cell lymphoma, highlighting an important and unusual diagnostic clue for clinicians.

This case report of mantle cell lymphoma presenting solely as a cutaneous nodule in an elderly patient underscores the need to consider lymphoma in atypical skin lesions for accurate diagnosis.

This case report identifies mantle cell lymphoma as a rare cause of secondary thrombotic microangiopathy, diagnosed via kidney biopsy and resolved with chemotherapy, expanding the differential for this complication.

This review advocates for integrating BTK inhibitors into frontline MCL therapy for all patients, particularly for TP53-mutated disease, challenging the standard role of chemotherapy.

A pooled analysis of six phase 3 trials shows median overall survival for young, fit MCL patients improved from 4.9 years to not reached, driven by intensified frontline chemoimmunotherapy and transplant.

CT-based radiomics combined with machine learning accurately differentiates MCL from other lymphomas non-invasively, potentially improving diagnostic precision and guiding biopsies in treatment-naïve patients.

Frontline ibrutinib-rituximab improves progression-free survival over immunochemotherapy in older MCL patients, establishing a new chemotherapy-free standard of care option.

This review provides a framework for selecting frontline therapies for older MCL patients, weighing less-intensive chemoimmunotherapy against novel agents like BTK inhibitors based on patient-specific factors.

This SHINE trial analysis shows ibrutinib's PFS benefit with BR is consistent across exposure levels, supporting dose reductions for toxicities like atrial fibrillation without compromising efficacy.

A 2022 real-world Japanese study shows chemotherapy remains dominant frontline while BTKis are common second-line, with physicians prioritizing quality of life for BTKi-treated patients over tumor response.

Adding venetoclax to RBAC chemo-immunotherapy improves 2-year progression-free survival to 60% for older, high-risk MCL patients, validating a new risk-stratified, fixed-duration frontline treatment.

The EHA-EU MCL network published comprehensive guidelines standardizing risk-stratified diagnosis and treatment for MCL, covering young/fit and elderly patients in both frontline and relapsed/refractory settings.

In newly diagnosed MCL, ATM deletion predicts shorter progression-free survival in TP53 wild-type patients, whereas ATM mutation may indicate a better prognosis, highlighting their distinct prognostic roles.

Single-cell analysis reveals pre-existing minor clones with unique mutations drive relapse, explaining patient-specific progression and the need to target intratumoral heterogeneity at diagnosis.

This review argues that new agents like BTKi are disrupting the frontline MCL standard of care, challenging ASCT's role and demanding personalized, risk-adapted treatment guidelines to resolve clinical uncertainty.

This review summarizes the integration of BTK inhibitors into frontline MCL therapy and the emerging role of MRD, providing a treatment algorithm for managing newly diagnosed patients.

In elderly, frontline MCL, this SHINE secondary analysis shows achieving a complete response is critical for long-term PFS, and adding ibrutinib to BR significantly increases CR rates.

Retrospective data show B symptoms and CBV conditioning negatively impact survival post-ASCT in MCL, supporting BeEAM conditioning and risk-adapted strategies for consolidation.

This phase II trial protocol compares chemo-free ibrutinib/venetoclax/rituximab versus ibrutinib-chemoimmunotherapy in treatment-naive elderly MCL, aiming to establish a new frontline standard.

Serum beta-2 microglobulin is a critical prognostic biomarker in lymphoma, including MCL, where it reflects tumor burden and is a key component of the MIPI risk score.

In untreated mantle cell lymphoma, adding acalabrutinib to bendamustine-rituximab significantly improves progression-free survival with manageable toxicity, offering a potentially safer chemoimmunotherapy combination than ibrutinib-based regimens.

This review summarizes recent phase II/III trial data supporting the integration of covalent BTK inhibitors into frontline MCL therapy, proposing new treatment algorithms for this setting.

This meta-analysis in TP53-mutated MCL supports targeted therapy frontline and CAR-T or transplant in relapse, but confirms poor long-term survival, highlighting the need for novel approaches.

A US claims analysis shows MCL treatment costs increase substantially with each line of therapy, driven by hospitalizations, underscoring the economic need for more effective, durable frontline regimens.